Yposkesi Launches LentiSure Lentiviral Vector Production Platform

New LV platform provides CAR-T developers with more robust capacity to drive clinical development and commercial cell and gene therapy pipelines.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Yposkesi, SK pharmteco’s clinical and commercial viral vector manufacturing arm for cell and gene therapies, launched LentiSure, an optimized Lentiviral (LV) Vector manufacturing platform for increasing lentivirus production efficiency and robustness. Lentivirus or LV vectors are used to produce cell-based immuno-oncology therapies. Their robustness as a gene delivery system is vital in determining the success of any cell-based cancer treatment.    LentiSure’s capabilities in producing LV vect...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters